A pharmacogenetic imaging study found that amphetamine’s effects depended on both COMT genotype and working-memory load. A drug response that appeared favorable under one condition could be absent or unfavorable under another.
Mattay and colleagues studied healthy volunteers selected according to COMT genotype and other eligibility criteria. They examined prefrontal fMRI responses during a working-memory task under amphetamine and comparison conditions.
The COMT variation concerns an enzyme involved in catecholamine metabolism. It is an inherited characteristic, not a toxicology measurement of the drug in blood or evidence that a person is currently impaired.
The authors reported improved prefrontal efficiency with amphetamine in val/val participants across task difficulty levels. In met/met participants, amphetamine did not improve efficiency at low-to-moderate load and was associated with deterioration at high load.
The interpretation of cortical efficiency depends on the relationship between activation and task performance. It is not simply a statement that less activation is always better or more activation is always harmful.
The researchers related their findings to an inverted-U account in which increasing dopamine-related signaling can help or hinder function depending on the starting point. That is a mechanistic interpretation of the experimental pattern, rather than direct measurement of a personal optimal dopamine level.
Participants were carefully selected to reduce confounding, including restrictions on prior stimulant exposure, medical conditions and smoking. This control improves the specific comparison but narrows its applicability to heterogeneous clinical populations.
A group association does not validate a genetic test for choosing a person’s medication or predicting an adverse event. Replication, prospective prediction and clinically relevant outcomes are separate requirements.
The study’s main lesson is that genotype, task demand and baseline function can all affect a stimulant result. It does not establish that one genotype guarantees enhancement, impairment or safe performance in daily life.
Related reading: COMT genotype and attention effects.